Abstract: For any given target trajectory, asymptotic tracking error convergence can be achieved as the number of iterations tends to infinity by applying existing ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Many in the AI community believe that the next major revolution will be the era of self-improving AI where AI can improve itself without human intervention. The argument is: as models grow more ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Who do you think would win a fight between a python and a crocodile in Florida? Generally, we would look to real-life examples for clues, but surprisingly, there isn’t very much of that. While there ...

Innovation is transformative. It’s why we ride in a Mustang instead of on a mustang. Centuries of knowledge now fit in the palm of our hand. Products move from reliable to revolutionary. Yet ideas ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...